Investing in Quest Diagnostics Incorporated (DGX)  ➔  Intrinsic value

Prev. close$129.43 
ModelValueUpside
Chepakovich$105.41-19%
Graham-Dodd$55.71-57%
Graham$172.80+34%
Previous Close$129.43  
Valuation MethodValuePotential 
Chepakovich Model$105.41-19%recalculate
Graham-Dodd$55.71-57%recalculate
Graham Formula$172.80+34%recalculate

Latest news

Company description

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated has a strategic collaboration with hc1; and strategic relationships with Clinical Genomics Pty Ltd and Anthem Inc. The company was founded in 1967 and is headquartered in Secaucus, New Jersey.